Clinical Manifestations and Management of Terbinafine-Induced Acute Generalized Exanthematous Pustulosis

Table 1

Basic information on 32 patients with terbinafine-induced acute generalized exanthematous pustulosis.

Parameters		Values
Sex	Male	17 (53.1%)
	Female	15 (46.9%)
Age	Years	55 (6,84)
Country	USA	7 (21.9%)
	UK	5 (15.6%)
	Belgium	3 (9.4%)
	France	3 (9.4%)
	Tunisia	3 (9.4%)
	Turkey	4 (12.5%)
	Switzerland	2 (6.25%)
	Japan, India, Italy, Australia, and Portugal	1 (3.1%)
Dosage	250 mg daily	16 (50.0%)
Onset time	Days	8 (1, 77)^b
	≤7	14 (43.8%)
	7–14	11 (34.4%)
	21–77	7 (21.9%)
Indication (31)^a	Onychomycosis	17 (53.1%)
	Tinea cruris	5 (15.6%)
	Tinea corporis	3 (9.4%)
	Tinea pedis	3 (9.4%)
	Tinea capitis	1 (3.1%)
	Tinea manum	1 (3.1%)
	Cutaneous candidiasis	1 (3.1%)
Past skin diseases (4)^a	Psoriasis	3 (9.4%)
	Bullous pemphigoid	1 (3.1%)
History of disease (5)^a	Diabetes	3 (9.4%)
	Hypertension	2 (6.3%)
	Ischaemic heart disease	1 (3.1%)
	Chronic heart failure	1 (3.1%)
	Hypercholesterolemia	1 (3.1%)
	Chronic obstructive pulmonary disease	1 (3.1%)
Concomitant drugs	Ciclopirox, enalapril, simvastatin, warfarin, isosorbide, diltiazem, metoprolol, glyburide, glucophage, prednisolone, hydrochlorothiazide, gemfibrozil, and aspirin	6 (18.8%)

^arepresents the number of patients out of 32 on which information regarding this particular parameter was provided. ^bMedian (minimum-maximum).